Acute HCV/HIV Coinfection Is Associated with Cognitive Dysfunction and Cerebral Metabolite Disturbance, but Not Increased Microglial Cell Activation

Lucy J. Garvey1,2, Nicola Pavese3, Anil Ramlackhansingh3, Emma Thomson1,2, Joanna M. Allsop4, Marios Politis3, Ranjababu Kulasegaram5, Janice Main1,2, David J. Brooks3, Simon D. Taylor-Robinson1, Alan Winston1,2

1 Department of Medicine, Imperial College London, London, United Kingdom, 2 Department of HIV and GU Medicine, Imperial College Healthcare NHS Trust, London, United Kingdom, 3 Neurosciences Section, Division of Experimental Medicine, Imperial College London, London, United Kingdom, 4 Imaging Sciences Department, Medical Research Council (MRC) Clinical Sciences Centre, Imperial College London, London, United Kingdom, 5 Department of HIV and GU Medicine, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

Abstract

Background: Microglial cell activation and cerebral function impairment are described in both chronic hepatitis C viral (HCV) and Human-Immune-Deficiency viral (HIV) infections. The aim of this study was to investigate the effect of acute HCV infection upon cerebral function and microglial cell activation in HIV-infected individuals.

Methods: A case-control study was conducted. Subjects with acute HCV and chronic HIV coinfection (aHCV) were compared to matched controls with chronic HIV monoinfection (HIVmono). aHCV was defined as a new positive plasma HCV RNA within 12 months of a negative RNA test. Subjects underwent neuro-cognitive testing (NCT), cerebral proton magnetic resonance spectroscopy (1H-MRS) and positron emission tomography (PET) using a 11C-radiolabeled ligand (PK11195), which is highly specific for translocator protein 18 kDa receptors on activated microglial cells. Differences between cases and controls were assessed using linear regression modelling.

Results: Twenty-four aHCV cases completed NCT and 1H-MRS, 8 underwent PET. Of 57 HIVmono controls completing NCT, 12 underwent 1H-MRS and 8 PET. Subjects with aHCV demonstrated on NCT, significantly poorer executive function (mean [SD] error rate 26.50(17.87) versus 19.09(8.12), p = 0.001) and on 1H-MRS increased myo-inositol/creatine ratios (mI/Cr, a marker of cerebral inflammation) in the basal ganglia (ratio of 0.71(0.22) versus 0.55(0.23), p = 0.03), compared to subjects with HIVmono. On PET imaging, no difference in 11C-PK11195 binding potential (BP) was observed between study groups (p > 0.10 all cerebral locations), however lower BPs were associated with combination antiretroviral therapy (cART) use in the parietal (p = 0.01) and frontal (p = 0.03) cerebral locations.

Discussion: Poorer cognitive performance and disturbance of cerebral metabolites are observed in subjects with aHCV compared to subjects with HIVmono. Higher 11C-PK11195 BP was not observed in subjects with aHCV, but was observed in subjects not on cART.

Copyright: © 2012 Garvey et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The NIHR Biomedical Facility at Imperial College London funded infrastructure support. SDT-R holds grants from the Wellcome Trust, the United Kingdom National Institute for Health Research (NIHR), the British Medical Research Council and the European Union (Framework 7). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: lucy.garvey@nhs.net

Introduction

Central nervous system disturbances are well described in patients with chronic HIV infection and more recently, in those with chronic hepatitis C (HCV) infection in the absence of significant liver disease[1–3]. Abnormalities, compared to matched control populations, demonstrable using cerebral function measures such as neurocognitive testing (NCT) and proton magnetic resonance spectroscopy (1H MRS) have been shown in both patient groups[4,5]. Such cerebral deficits may be greater in individuals coinfected with HIV and chronic HCV, compared to individuals with HIV monoinfection [6–9]. Both viruses can be identified in cerebrospinal fluid and brain tissue [9–11] and although the pathophysiology of these cerebral disturbances remain unclear, microglial cell activation has been proposed as a promoter of neurodegeneration and inflammation in both HIV-associated encephalopathy [12] and chronic HCV-associated cognitive decline [13].

The isoquinoline PK11195 is a highly specific, high-affinity ligand for translocator protein 18 kDa receptors on activated microglial cells. PK11195 can be radio-labeled with carbon 11...
(11C) and injected as a tracer during cerebral positron emission tomography (PET) scanning to provide non-invasive, quantification of microglial cell activity at a cellular level. This technique has been histologically validated in animals [14,15] and humans [16] and used to demonstrate microglial activation in a variety of human neurological disorders, including in patients with chronic HCV in the presence or absence of cirrhosis [17–20]. To date, increased binding of PK11195 has been demonstrated only in HIV-infected subjects with severe HIV encephalopathy [21], with increased binding not reported in asymptomatic HIV-infected subjects or in those with mild cognitive deficits [22].

The impact of acute HCV infection acquisition upon cerebral function parameters remains poorly understood. Secondary to a recent epidemic of acute HCV infection in HIV-infected men who have sex with men, this phase of infection is now frequently identified in clinical practice [23,24]. Earlier work from our group [25] identified a reduction in inflammatory cerebral metabolites in the basal ganglia of 10 subjects with acute HCV and chronic HIV infection. The aim of this study, was to further elucidate any changes in cerebral function observed in subjects during acute HCV infection via the assessment of cognitive performance and cerebral metabolites and to assess for any evidence of increased microglial cell activation via PET imaging.

**Methods**

Ethics approval was obtained from the National Research Ethics Service in separate applications to undertake the NCT studies (07/H0803/128) and 1H MRS (08/H0712/15). For the administration of 11C PK11195 (09/H0712/17) permission was also obtained from the Administration of Radioactive Substances Advisory Committee (ARSAC) of the UK. All participants provided written, informed consent prior to commencing any study procedures.

All subjects completed NCT studies with a sub-set enrolled in 1H-MRS and a smaller group undergoing PET examination. All subjects were recruited during routine HIV clinic attendances and were eligible if aged over 18 years with chronic HCV infection (HIV-1 antibody positive for a minimum of 6 months). Exclusion criteria included current AIDS-defining illnesses, any active neurological complaint or disease, encephalopathy, untreated syphilis, chronic hepatitis B infection, current receipt of interferon and ribavirin treatment, hepatic synthetic functional impairment (a serum albumin below 30 g/dL or prolonged prothrombin time), use of benzodiazepines or recreational drugs within the past month and alcohol consumption in excess of an average of 20 g/day in the past six months.

**Selection of Subjects with Acute Hepatitis C**

Subjects with HIV/acute HCV coinfection (aHCV cases) were required to have acute HCV, defined by a new positive plasma HCV RNA test within 12 months of a negative HCV RNA test.

**Selection of Control Subjects**

HIV-infected individuals without hepatitis C co-infection (HIVmono), were recruited as control subjects. All were required to be HIV antibody or RNA negative within the past year, with normal liver function tests thereafter. For participants undergoing 1H-MRS and PET, subjects were matched to aHCV cases according to age, time-elapsed since HIV diagnosis, current CD4+ cell count, whether currently receiving combination antiretroviral therapy (cART), and type of cART in those receiving therapy (non-nucleoside reverse transcriptase inhibitor (NNRTI)-based) or protease inhibitor (PI)-based).

**Neurocognitive Test (NCT)**

A computerised assessment of cognitive performance was undertaken (CogState™, Melbourne, Australia) which has been previously validated in HIV infection [26] and used in HIV treatment studies [27]. It assesses 8 cognitive domains (psychomotor function, identification, monitoring and matched learning; associate learning, visual learning and working memory; and executive function). Overall cognitive speed, performance accuracy, executive function and composite \( Z \)-scores were then calculated for each subject.

**Proton Magnetic Resonance Spectroscopy (1H-MRS)**

1H-MRS was performed on an Achieva 1.5 Tesla scanner (Philips NV, Best, Netherlands) at the Robert Steiner Magnetic Resonance Unit, Hammersmith Hospital, London, UK. Examination included sagittal, coronal and axial T1-weighted images of the brain and T2-weighted axial double spin echo images. 1H-MRS was performed in 3 voxel locations: frontal white matter (FWM), frontal grey matter (FGM) and the basal ganglia (BG), using a double spin echo point resolved spectroscopy (PRESS) sequence with the following settings: echo time (TE) 36 ms, repetition time (TR) 3000 ms, 2048 data points, spectral width of 2500 Hz and 128 data acquisitions. MR spectra were post-processed for automated water signal suppression and water shimming. \( T_1 \) and \( T_2 \)-weighted MR images were studied by an observer (LG) using a java-based version of the magnetic resonance user interface package (mMRIU Version Number: 3.0) [28], incorporating the AMARES algorithm [29] and metabolites expressed as ratios to cerebral creatine (Cr).

**Cerebral PET with 11C Labelled PK11195**

For subjects undergoing PET scanning, a strict 1:1 matching process of cases to controls was applied according to the selection of subjects above using the following criteria for matching; all gender matched, age (within 5 years), elapsed time since HIV diagnosis (within 5 years), current CD4+ count (within 100 cells/µL), nadir CD4+ count (within 100 cells/µL), whether currently receiving cART and type of cART (NNRTI or PI-based regimens matched).

PET scanning was performed on a PET-CT scanner (Whole body positron emission tomograph GE Discovery Rx PET/CT, GE Healthcare, Waukesha, Wisconsin) at the MRC Cyclotron Building, Hammersmith Hospital, Imperial College, London. A transmission CT scan and emission scan were performed with subjects lying in a partially-enclosed PET scanner and an injection of 11C-labeled PK11195 radioactive ligand [R-enantiomer] was given as a smooth bolus. The target quantity was 296 MBq (8.00 mCi, approximately 1.7 mSv tissue dose). Parametric images of specific \( ^{11} \text{C} \) –[R]-PK11195 binding potential (BP), a measure reflecting \( \text{Bmax/Kd} \), were calculated using a basis function implementation of a simplified reference tissue model [30]. The possible widespread expression of TSPO in patients with viral infections makes it difficult to select a reference region representing nonspecific PK uptake in the brain. We therefore used a supervised clustering procedure to identify reference clusters of voxels in the grey matter having PK11195 time activity curves mirroring those of a standardized control population, as previously described [31].

For each patient, PK11195 BP values in the parietal, occipital, frontal, temporal, ventral striatum, caudate, putamen and thalamus regions were calculated by applying standardised object maps to normalized \( ^{11} \text{C} \)–[R]-PK11195 BP images in Analyze software (Analyze AVW, Mayo Clinic, US). Spatial normalization of parametric images into standard stereotactic space (Montreal Cerebral Function in Acute HCV/HIV Coinfection
Neurocognitive Testing Results

No significant differences were observed in overall composite Z-score or performance accuracy between study groups (p = 0.05 all observations, Table 2). However individuals with aHCV had significantly poorer executive function performance than HIVmono in the univariate analysis (p = 0.02, 95% CI 0.09, 1.07). When factors associated with poorer executive function were examined in a multivariate model, no association with receiving cART was observed (p = 0.37, 95% CI −18.8, 7.1), however lower nadir CD4+ cell count and aHCV study group were independently associated with poorer executive function performance (Table 3). In the univariate analysis, aHCV was associated with faster cognitive speed, but in the multivariate analysis, after adjustment for age, cART status, nadir and current CD4+ cell count, this association was no longer statistically significant (Table 3).

1H-MRS

Twenty-four aHCV subjects and 12-matched HIV mono subjects also underwent cerebral 1H-MRS. Subjects were matched according to age, gender and cART status. All 36 participants were male. Mean (SD) age and proportion receiving cART for aHCV and HIV mono were 40(8) versus 44(12) years and 71% versus 75% respectively. The mean (SD) time elapsed since last negative plasma HCV RNA in the aHCV patients prior to 1H-MRS was 24 weeks.

Cerebral metabolite ratios demonstrated a trend towards higher ml/Cr in the basal ganglia (BG) of aHCV subjects (p = 0.06, 95% CI for difference between groups −0.01, 0.32, see Table 2). In a multivariate model, both nadir CD4 count and aHCV study group were independently associated with higher ml/Cr (p = 0.05 and p = 0.03 respectively, Table 3). No significant associations were observed between BG ml/Cr and clinical parameters including the time elapsed since HCV RNA negative test, age or current CD4+ count (p-value >0.45 all values). Of note in subjects with aHCV, a strong association between higher BG ml/Cr and poorer executive function was observed (p = 0.006, 95% CI 0.00, 0.01).

Cerebral PET with 11C Labelled PK11195

16 subjects (8 in each group) then underwent a PET examination with all cases and controls matched for gender (all male) and HIV disease characteristics; numbers receiving no

---

Table 1. Patient demographics, clinical parameters and study participation of subjects completing neurocognitive testing (NCT) procedures.

| Study Participation | Clinical parameter | Acute HCV/HIV (aHCV) | HIV monoinfection (HIV mono) | Difference between groups, p-value* |
|---------------------|--------------------|----------------------|-----------------------------|-------------------------------------|
| Overall             | Number, n          | 24                   | 57                          |                                     |
|                     | Age (years), median [IQR] | 41 [36,44] | 47 [39, 56] | 0.003                              |
|                     | Male gender, n (%) | 24 (100)           | 50 (89)                     | 0.10                               |
|                     | Time-elapsed since HIV diagnosis (years), median [IQR] | 6 [3,12] | 11 [5,16] | 0.02                               |
|                     | Current CD4+ (cells/μL), median [IQR] | 590 [458, 745] | 505 [382, 783] | 0.29                               |
|                     | Nadir CD4+ (cells/μL), median [IQR] | 200 [215, 395] | 205 [88, 283] | 0.01                               |
|                     | Receiving antiretroviral therapy, n (%) | 17 (71) | 54 (95) | 0.006                              |
|                     | Current plasma HIV viral load below 50 c/mL, n (%) | 16 (67) | 54 (95) | 0.002                              |
|                     | HIV viral load of remaining subjects (c/mL), median [IQR] | 5797 [1136, 11758] | 14182 [1095, 15952] | 0.18                               |
|                     | Time elapsed since negative HCV RNA test (weeks), median [IQR] | 24 [20,32] | – | –                                  |
|                     | Current ALT (IU), median [IQR] | 213 [78, 237] | – | –                                  |
|                     | Peak ALT (IU), median [IQR] | 237 [180, 820] | – | –                                  |
|                     | HCV genotype, n (%) | 21 (88) | – | –                                  |
|                     | Most recent HCV RNA (c/mL), median [IQR] | 986855 [56650, 4315528] | – | –                                  |

Table 1 legend: HCV = hepatitis C virus; RNA = ribonucleic acid; ALT = alanine aminotransferase; IU = international units; *using Fisher’s exact test or t-test.

doi:10.1371/journal.pone.0038980.0001
Table 2. Results of cerebral function assessments and univariate regression analysis to investigate differences between subject groups.

| Cerebral function assessment, area of interest | Number of participants, n | Acute HCV/HIV (aHCV) | HIV monoinfection (HIVmono) | p-value | [95%CI] |
|-----------------------------------------------|---------------------------|-----------------------|----------------------------|---------|--------|
| NCT                                           |                           |                       |                            |         |        |
| Participants on cART, n(%)                     | 24                        | 57                    |                            |         |        |
| Cognitive speed (logms)                        | 17 (71%)                  | 54 (95%)              |                            |         |        |
| Accuracy (arc.proportion correct)              | 10.57 (0.28)              | 10.73 (0.33)          | 0.05                       | [-0.99, 0.01] |
| Executive function (error rate)                | 26.50 (17.87)             | 19.09 (8.12)          | 0.02                       | [0.09, 1.07] |
| PK11195 BP Number of participants, n           | 8                         | 8                     |                            |         |        |
| Participants on cART, n(%)                     | 6 (75%)                   | 6 (75%)               |                            |         |        |
| Frontal grey matter                            | NAA/Cr 1.42 (0.25)        | 1.35 (0.10)           | 0.32                       | [-0.41, 1.21] |
|                                               | Cho/Cr 0.59 (0.12)        | 0.63 (0.17)           | 0.31                       | [-2.38, 0.77] |
|                                               | mI/Cr 0.70 (0.28)         | 0.62 (0.13)           | 0.39                       | [-0.10, 0.25] |
| Frontal white matter                           | NAA/Cr 1.53 (0.32)        | 1.48 (0.26)           | 0.63                       | [-0.42, 0.68] |
|                                               | Cho/Cr 1.04 (0.20)        | 1.02 (0.19)           | 0.73                       | [-0.69, 0.98] |
|                                               | mI/Cr 0.96 (0.48)         | 0.83 (0.54)           | 0.47                       | [-0.23, 0.49] |
| Basal ganglia                                  | NAA/Cr 1.71 (0.25)        | 1.65 (0.29)           | 0.54                       | [-0.45, 0.84] |
|                                               | Cho/Cr 0.77 (0.12)        | 0.80 (0.19)           | 0.36                       | [-2.27, 0.85] |
|                                               | mI/Cr 0.71 (0.22)         | 0.55 (0.23)           | 0.06                       | [-0.01, 0.32] |

| 1H-MRS                                         |                           |                       |                            |         |        |
| Participants on cART, n(%)                     | 17 (71%)                  | 9 (75%)               |                            |         |        |
| Frontal grey matter                            | NAA/Cr 1.42 (0.25)        | 1.35 (0.10)           | 0.32                       | [-0.41, 1.21] |
|                                               | Cho/Cr 0.59 (0.12)        | 0.63 (0.17)           | 0.31                       | [-2.38, 0.77] |
|                                               | mI/Cr 0.70 (0.28)         | 0.62 (0.13)           | 0.39                       | [-0.10, 0.25] |
| Frontal white matter                           | NAA/Cr 1.53 (0.32)        | 1.48 (0.26)           | 0.63                       | [-0.42, 0.68] |
|                                               | Cho/Cr 1.04 (0.20)        | 1.02 (0.19)           | 0.73                       | [-0.69, 0.98] |
|                                               | mI/Cr 0.96 (0.48)         | 0.83 (0.54)           | 0.47                       | [-0.23, 0.49] |
| Basal ganglia                                  | NAA/Cr 1.71 (0.25)        | 1.65 (0.29)           | 0.54                       | [-0.45, 0.84] |
|                                               | Cho/Cr 0.77 (0.12)        | 0.80 (0.19)           | 0.36                       | [-2.27, 0.85] |
|                                               | mI/Cr 0.71 (0.22)         | 0.55 (0.23)           | 0.06                       | [-0.01, 0.32] |

| Ventral striatum                               | 0.18 (0.10)               | 0.22 (0.13)           | 0.45                       | [-3.46, 1.64] |
| Caudate                                        | 0.08 (0.04)               | 0.09 (0.08)           | 0.69                       | [-5.76, 3.94] |
| Putamen                                        | 0.21 (0.11)               | 0.28 (0.14)           | 0.29                       | [-3.49, 1.14] |
| Thalamus                                       | 0.52 (0.31)               | 0.55 (0.17)           | 0.84                       | [-1.14, 1.19] |
| Parietal                                       | 0.07 (0.06)               | 0.10 (0.06)           | 0.33                       | [-7.56, 2.71] |
| Temporal                                       | 0.13 (0.03)               | 0.16 (0.05)           | 0.16                       | [-10.82, 1.99] |
| Occipital                                      | 0.13 (0.04)               | 0.19 (0.09)           | 0.10                       | [-6.58, 0.54] |
| Frontal                                        | 0.83 (0.40)               | 1.03 (0.27)           | 0.26                       | [-1.34, 0.40] |

| Legend Table 2: FGM = frontal grey matter; FWM = frontal white matter; BG = basal ganglia; NAA = N-acetyl aspartate; Cr = creatine; Cho = choline; mI = myo-inositol peak. |
|doi:10.1371/journal.pone.0038980.t002 |
cART, NNRTI-based and boosted PI-based cART were 2, 4 and 2 subjects in each group, respectively. The mean number of weeks elapsed since most recent negative plasma HCV RNA test in this smaller aHCV sub-group was 20.5 (range 16–28) indicating very recent acquisition in all subjects.

The reference regions were within the cortex and no patterns were observed in their extent/location. No overlap with reference regions and regions of interest occurred. Overall PK11195 BPs for each cerebral region of interest are shown in Table 2. No significant difference between aHCV cases and controls was observed in any location (p>0.10 all values), but in the multivariate analysis, receiving cART was independently associated with significantly lower PK11195 BP in the frontal (p = 0.05, 95% CI −0.82, 0.02) and parietal locations (p = 0.05, 95% CI −0.14, −0.01), see Table 4 and Figure 1).

Discussion

In this study, we have demonstrated that acquisition of acute HCV in HIV-infected subjects is associated with changes in cerebral function measures using a cognitive assessment and cerebral 1H-MRS. We did not however, demonstrate significant differences in PK11195 BP when using PET imaging as an in vivo marker of microglial cell activation.

Acute HCV was independently associated with poorer executive function performance in this study, despite the relatively well-preserved CD4+ cell counts and young age of subjects enrolled. Importantly, these differences remained statistically significant after adjustment for the lower proportion of aHCV subjects receiving cART. While this form of higher cognitive processing performance associated with the acquisition of HCV infection.

...
The changes to mI/Cr ratios that were observed may represent increased neuroinflammation and glial proliferation during the early phase of HCV. Forton et al. [36] have previously described increases of mI/Cr ratio in patients with chronic HCV, in the frontal white matter, rather than the BG. As the BG has a higher blood flow per unit volume [37] than other cerebral locations, it is possible that greater and earlier exposure of this cerebral location may explain why the changes observed in our study during acute infection had not yet evolved in other areas of the brain. Furthermore, BG dysfunction is associated with symptoms of fatigue and inertia in other neurological disorders and therefore inflammatory changes in this location, may explain the cognitive deficits we observed [38]. Interestingly and in contrast, in our earlier pilot study, we reported reductions in BG mI/Cr ratios in 10 subjects with acute HCV [25]. The changes we now report within a larger cohort may reflect a time dependent phenomena whereby dynamic changes in mI/Cr ratios are occurring during the early course of acute HCV infection. Once the process has begun, it may only take place during later stages of chronic HCV infection, as suggested by previous work [35].

Table 3. Results of univariate and multivariate analyses to examine clinical parameters associated with executive function, composite speed and basal ganglia mI/Cr ratio.

| Cerebral function assessment result | Poorer executive function | Poorer executive function | Faster Composite speed | Faster Composite speed | Higher basal ganglia mI/Cr ratio | Higher basal ganglia mI/Cr ratio |
|-------------------------------------|---------------------------|---------------------------|------------------------|------------------------|-------------------------------|-------------------------------|
| Clinical parameter                  | Univariate                | Multivariate              | Univariate             | Multivariate           | Univariate                   | Multivariate                   |
| p-value [95% CI]                    | p-value [95% CI]          | p-value [95% CI]          | p-value [95% CI]       | p-value [95% CI]       | p-value [95% CI]             | p-value [95% CI]             |
| aHCV study group                    | 0.02 [0.09, 1.07]         | 0.001 [5.8, 20.1]         | 0.05 [0.99, 0.00]      | 0.22 [-0.3, 0.1]       | 0.06 [-0.01, 0.32]           | 0.03 [0.02, 0.35]            |
| Nadir CD4+ count, per 100 cell/µL increase | 0.09 [-0.30, 0.02] | 0.001 [-0.1, -0.02] | 0.03 [-0.33, -0.02] | 0.10 [-0.01, 0.00] | 0.09 [-0.10, 0.01] | 0.05 [-0.11, 0.00] |
| Current CD4+ count, per 100 cell/µL increase | 0.70 [-0.12, 0.08] | - | 0.05 [-0.20, -0.00] | 0.78 [-0.05, 0.03] | 0.83 [-0.05, 0.04] | - |
| Age, per 10 year increase           | 0.68 [-0.28, 0.18]       | 0.59 [-3.9, 2.2]          | 0.03 [0.02, 0.47]      | 0.20 [-0.30, 1.30]     | 0.45 [-0.12, 0.06]           | - |
| Receiving cART                      | 0.70 [-0.95, 0.65]       | 0.37 [-18.8, 7.1]         | 0.42 [-0.47, 1.12]     | 0.79 [-0.34, 0.26]     | 0.58 [-0.14, 0.24]           | - |
| Plasma VL, per 1000 c/mL increase   | 0.37 [-0.38, 0.14]       | 0.06 [-0.54, 0.01]        | 0.82 [-0.01, 0.01]     | 0.59 [-0.01, 0.01]     | 0.84 [-0.01, 0.01]           | - |
| Time since HIV diagnosis, per 10 year increase | 0.34 [-0.06, 0.02] | 0.15 [-0.85, 0.13] | 0.57 [-0.03, 0.05] | 0.54 [-0.02, 0.01] | 0.81 [-1.58, 1.25] | - |

Table 4. Results of univariate and multivariate analyses to examine clinical parameters associated with occipital, parietal and frontal PK11195 Binding Potential (BP).

| Cerebral location of PK11195 binding Potential (BP) | Occipital | Parietal | Parietal | Frontal | Frontal |
|-----------------------------------------------------|-----------|----------|----------|---------|---------|
| Clinical parameter                                  | Univariate| Multivariate| Multivariate| Univariate| Multivariate| Multivariate| |
| p-value [95% CI]                                    | p-value [95% CI] | p-value [95% CI] | p-value [95% CI] | p-value [95% CI] | p-value [95% CI] | p-value [95% CI] | |
| aHCV study group                                    | 0.10 [-0.15, 0.01] | 0.11 [-0.13, 0.02] | 0.33 [-0.10, 0.03] | - | 0.26 [-0.58, 0.17] | - |
| Nadir CD4+ count, per 100 cell/µL increase          | 0.65 [-0.02, 0.03] | - | 0.18 [-0.01, 0.03] | - | 0.24 [-0.04, 0.14] | - |
| Current CD4+ count, per 100 cell/µL increase        | 0.68 [-0.02, 0.03] | - | 0.06 [-0.01, 0.03] | 0.14 [-0.01, 0.02] | 0.13 [-0.02, 0.17] | 0.29 [-0.04, 0.14] |
| Age, per 10 year increase                           | 0.62 [-0.05, 0.03] | - | 0.48 [-0.04, 0.02] | - | 0.35 [-0.87, -0.07] | - |
| Receiving cART                                      | 0.06 [-0.19, 0.00] | 0.07 [-0.18, 0.09] | 0.01 [-0.15, -0.02] | 0.03 [-0.14, -0.01] | 0.03 [-0.87, -0.07] | 0.05 [-0.82, 0.02] |
perhaps refuted and last theory supported by the findings of Grover and colleagues who describe increased PK11195 BP, interpreted as microglial cell activation, in patients with chronic HCV without significant liver disease and by the findings of Cagnin and colleagues who observed similarly increased PK11195 BP in a small number of subjects with advanced, chronic HCV infection using the same PET methodologies [36]. It is therefore feasible that during the acute period of infection with HCV, there is no change to levels of microglial cell activation. It is known that microglia are recruited from circulating macrophage/monocytes and animal model data have demonstrated that this process may take several months following cerebral insult [39]. The mean time elapsed since negative HCV RNA test was 21 weeks in the 8 acute HCV subjects of this PET study, which is likely to be an over-estimation of actual time since viral transmission. It is therefore possible, if our study was repeated several months later, different results would be observed. Another explanation for our findings is that due to ligand-factors including high plasma-protein binding, non-specific binding or low brain uptake, PK11195 as a neurotracer was insufficiently sensitive to detect subtle changes in microglial activation in such neurologically asymptomatic subjects, and that use of other, newly available, alternative ligands including $^{11}$C PBR-28 [40], $^{11}$CDPA-713 [41] or $^{11}$CDAA-1106 [42] may alter our findings. Further PET studies are needed to answer these questions.

Microglial activation is a feature of the chronic phase of HCV infection, we postulate that the effects of circulating cytokines (rather than microglial cell activation) may be responsible for the cerebral function differences we observed in this study. The neuropsychological effects of endogenous circulating cytokines and chemokines are observed in the presence of chronic infection and are very similar to the CNS effects of therapeutically-administered interferon.

Interestingly, we observed an association between those receiving cART and lower PK11195 BP values in some cerebral locations, which has not been previously described and which suggests lower levels of microglial cell activation in subjects receiving cART, irrespective of acute HCV status. While only small numbers of patients were sampled and few number of subjects were not receiving cART, this suggests that, similar to systemic levels of inflammation, neuroinflammation may also be reduced in effectively treated HIV-infected subjects. Over time, ongoing inflammation within the CNS may result in progressive neuronal damage with subsequent clinical sequelae and these data suggest an additional potential benefit from cART, which although may be postulated, have not to date been clearly demonstrated.

Associations between recreational drug use, concurrent sexually-transmitted infections and acquisition of acute HCV have been described which may influence cerebral metabolite ratios and have a negative impact upon cognitive performance [43]. For this reason, any subject with recent recreational drug misuse (within past 4 weeks) or current sexually transmitted infection known to cause CNS disease (such as early syphilis) were excluded. It remains possible, however, that high rates of historical drug misuse (with resultant cerebral damage) may have contributed to our observations. A further limitation of this work is the absence of longitudinal follow-up studies to identify if any increase of $^{11}$C PK11195 BP evolves with duration of HCV coinfection, although it should be noted that ethical considerations on radiation dosage has precluded the evaluation of such longitudinal PET studies to date. Finally, the sample size for the $^1$H-MRS and PET imaging studies, limits our ability to detect subtle differences and associations. PET scans with PK11195 are too costly for large-scale studies, but our work is of similar size to previous physiological PET studies and larger than other previously published work in this area.

In summary, we report changes to cerebral function measures in subjects with acute HCV, but have not found differences of PK11195 BP, representing microglial cell activation, in the early months of HCV viraemia. If microglial activation is a late feature of chronic HCV infection, then there may be an additional clinical reason to treat and eliminate HCV in the acute phase where possible, as therapy-response rates are higher and recommended treatment courses shorter [44].

Author Contributions
Conceived and designed the experiments: LG AW STR NP DB. Performed the experiments: LG AW STR JMA. Analyzed the data: LG NP AW MP AR STR. Contributed reagents/materials/analysis tools: RK ET JM LG AW JMA. Wrote the paper: LG AW STR NP.
References

1. Tozzi V, Balestra P, Serraino D, Bellagamba R, Corpolongo A, et al. (2005) Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses 21: 706–713.

2. Forton DM, Alioppo JM, Main J, Foster GR, Thomas HC, et al. (2001) Evidence for a cerebral effect of the hepatitis B virus. Lancet 358: 38–39.

3. Forton DM, Thomas HC, Murphy CA, Alioppo JM, Foster GR, et al. (2002) Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 35: 433–439.

4. Tracey I, Carr CA, Guimaraes AR, Worth JL, Navia BA, et al. (1996) Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: A proton magnetic resonance spectroscopic study. Neurology 46: 783–786.

5. Weisenborn K, Krause J, Bokemeyer M, Hecker H, Schuler A, et al. (2004) Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 41: 845–851.

6. Ryan EL, Morgan S, Isaacs K, Naseer M, Gerits P (2004) Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 62: 957–962.

7. Richardson JL, Nowicki M, Danley K, Martin EM, Cohen MH, et al. (2005) Neuropsychological functioning in a cohort of HIV- and hepatitis C virus-infected women. AIDS 19: 1659–1667.

8. Letendre SL, Chermer M, Ellis RJ, Marquie-Beck J, Gragg B, et al. (2005) The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS 19: S72–78.

9. Murray JF, Fishman SL, Ryan E, Eng FJ, Walensky JL, et al. (2008) Hepatitis C and cognitive dysfunction in a blood donor cohort. J Neurovirol 15: 267–276.

10. Laskus T, Radkowski M, Bednarska A, Wilkinson J, Adair D, et al. (2000) Hepatitis C virus-seroconversion is associated with improved cognitive function in human immunodeficiency virus type 1-infected subjects with and without cognitive impairment. J Neurovirol 6: 262–271.

11. Grover VP, Chatterjee A, Nanda RC, Bhat BM, et al. (2002) Neuroimaging studies in chronic hepatitis C virus infection: a review. Neurol India 50: 109–113.

12. Forton DM, Koffi K, Thomas HC, Turner JM, Graf A, et al. (2001) Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med 42: 1387–1393.

13. Forton DM, Alioppo JM, Cox JJ, Hamilton G, Wenes K, et al. (2005) A review of the role of hepatitis C virus in the brain. J Neurovirol 11: 231–237.

14. Gallo R, Martin A, Arranz MJ, Pareto D, Purroy J, et al. (2007) Imaging brain inflammation with [11C]-R-PK11195 in patients with AIDS dementia complex: A proton magnetic resonance spectroscopic study. Neurology 67: 1001–1010.

15. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, et al. (2007) Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS dementia complex: A proton magnetic resonance spectroscopic study. J Hepatol 41: 845–851.

16. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, et al. (2000) The peripheral benzodiazepine binding site in the brain in multiple sclerosis: enantiomers of [N-methyl-11C]PK 11195 and comparison of their behaviours as ligands for the peripheral benzodiazepine receptor. J Cereb Blood Flow Metab 27: 1975–1986.

17. Katsiyiannis K, Thomas HC, Turner JM, Graf A, et al. (2001) Imaging brain inflammation with [11C]PK11195 by PET and induction of the peripheral-type benzodiazepine receptor receptor after transient focal ischemia in rats. J Cereb Blood Flow Metab 21: 404–412.

18. Rojas S, Martin A, Arranz MJ, Pareto D, Purroy J, et al. (2007) Imaging brain inflammation with [(11)C]PK11195 by PET and induction of the peripheral-type benzodiazepine receptor after transient focal ischemia in rats. J Cereb Blood Flow Metab 27: 1975–1986.